Literature DB >> 28688543

Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer?

Claudio Puoti1, Maria Giuseppa Elmo2, Daniela Ceccarelli3, Michela Ditrinco4.   

Abstract

Until the end of the 90's of the last century, rather little attention was paid to the issue of the non-alcoholic fatty liver disease (NAFLD), perhaps due to the fact that the newly discovered hepatitis C virus did attract a paramount interest of hepatologists and researchers. On the other side, fatty liver was considered a relatively uncommon cause of liver damage, occurring almost exclusively in obese females, often associated with non-insulin dependent diabetes mellitus (NIDDM), and with a relatively benign prognosis. Due to the complexity of international available guidelines, we decide to approach the main unsolved issues on this topic in the form of a dialog between a hepatologist and a man suffering from NAFLD, trying to give evidence-based answers to the more frequently asked questions from patients and their GPs. This is the third instalment of the Trilogy of Dr. Calm, a skilled hepatologist who will try to clearly explain to his patient Mr. Frightened the natural history of NAFLD, the diagnostic workup, indications for liver biopsy and suggested medical treatments, advicing him on the importance of dietary intervention and lifestyle modifications.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Diet; Metabolic syndrome; NAFLD; NASH; Non alcoholic; Steatosis

Mesh:

Year:  2017        PMID: 28688543     DOI: 10.1016/j.ejim.2017.06.024

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.

Authors:  Eline H van den Berg; Eke G Gruppen; Richard W James; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2018-11-19       Impact factor: 5.922

2.  Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo.

Authors:  Simon Bucher; Arnaud Tête; Normand Podechard; Marie Liamin; Dounia Le Guillou; Martine Chevanne; Cédric Coulouarn; Muhammad Imran; Isabelle Gallais; Morgane Fernier; Quentin Hamdaoui; Marie-Anne Robin; Odile Sergent; Bernard Fromenty; Dominique Lagadic-Gossmann
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

3.  A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment.

Authors:  Chang-Gue Son
Journal:  Integr Med Res       Date:  2018-02-02

4.  Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease.

Authors:  Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Ratanesh K Seth; Philip Busbee; Hasan Alghetaa; Dwayne E Porter; Geoff I Scott; Bryan Brooks; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

5.  Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study.

Authors:  Eline H van den Berg; Eke G Gruppen; Hans Blokzijl; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Clin Med       Date:  2019-12-06       Impact factor: 4.241

6.  Plasma ApoE elevations are associated with NAFLD: The PREVEND Study.

Authors:  Eline H van den Berg; James P Corsetti; Stephan J L Bakker; Robin P F Dullaart
Journal:  PLoS One       Date:  2019-08-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.